Tamoxifen - Bone marrow and peripheral blood stem cell
Essential information
- Obligatory
-
See: Maligancy
- Discretionary
-
Less than 12 weeks after completion of treatment with tamoxifen, refer to Designated Clinical Support Officer.
Supporting information
- See if relevant
- Reason for change:
- To clarify that use of Tamoxifen for non-malignant conditions is not a contraindication to donation.
- Version details:
BM-DSG Edition 203 Release 38 (07 October 2020)